6 Best Peptides for Liver Fibrosis

What to Know Before Choosing a Peptide for Liver Fibrosis

Liver fibrosis is the progressive accumulation of scar tissue inside the liver, the result of chronic injury driving a wound-healing response that never quite turns off. The liver's structural cells, called hepatic stellate cells, shift into an activated state and begin producing excess collagen. Over time that collagen builds up in a way that stiffens and scars the organ, advancing through stages from mild scarring to the irreversible end-stage known as cirrhosis. The earlier stages, roughly F1 through F3 on the standard staging scale, are considered potentially reversible, which is exactly where most peptide research is focused.

Every compound covered here earned its place for one reason: people are using it, or actively discussing it, for liver fibrosis. That is the whole eligibility test. FDA approval, randomized trial data, and commercial availability are not the gates. Semaglutide, which has a full Phase 3 trial and FDA approval for this specific condition, sits in the same list as Ovagen and Svetinorm, which are peptide bioregulators with almost no indexed clinical data. Both kinds of compound belong, because both are part of the actual conversation around this goal. The evidence for each is described honestly inside its own entry, and the gaps are stated plainly rather than papered over.

The numbers on these entries are a spine for the list, not a verdict. They reflect how prominently each compound appears in the research literature and in real-world use, not a recommendation that one is better than another for you. That judgment depends on your situation, your liver's current staging, and what you build with your care team or with MyPeptidePal.

1. Semaglutide: The Only FDA-Approved Option for Liver Scarring

Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a hormone the gut releases after eating that signals the pancreas, the brain, and a range of other tissues. Most people encounter it as Wegovy or Ozempic, the branded versions used for weight management and type 2 diabetes. In August 2025, Wegovy became the first peptide drug ever approved by the FDA specifically for liver fibrosis, covering patients with metabolic dysfunction-associated steatohepatitis (commonly abbreviated MASH) and moderate to advanced scarring at stages F2 to F3.

The approval rests on the ESSENCE trial, a Phase 3 study of 1,197 patients published in the New England Journal of Medicine in April 2025. In that trial, 37 percent of patients on semaglutide showed a meaningful one-stage reduction in fibrosis compared to 23 percent on placebo. MASH resolution, meaning the inflammatory liver damage itself cleared, occurred in roughly 63 percent of treated patients. Those are meaningful numbers in a disease where effective options have historically been scarce.

How semaglutide works toward liver fibrosis involves several overlapping mechanisms. It improves insulin sensitivity in the liver, reduces the fat accumulation that triggers inflammation, and promotes significant weight loss, each of which independently reduces the lipotoxic stress that drives hepatic stellate cells into their scar-producing activated state. There is also evidence that GLP-1 receptors are expressed directly on hepatic stellate cells, potentially allowing direct anti-fibrotic signaling, though that piece of the mechanism is still being investigated.

The common side effects are gastrointestinal: nausea, vomiting, diarrhea, and abdominal discomfort, particularly during the early weeks of dose escalation. More serious risks include pancreatitis and gallbladder disorders. The drug is contraindicated in pregnancy and for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Semaglutide is prescription-only and accessible through physicians and telemedicine platforms. For the liver fibrosis indication specifically, the approval requires biopsy-confirmed MASH with F2 to F3 staging.

Community reports add texture to the trial data. Users on Reddit have described Fibroscan and MRI confirmation of significant liver improvement on semaglutide, including complete resolution of detectable fat and scarring in under a year for some individuals. Liver enzyme levels, tracked as ALT and AST, have been consistently reported to fall substantially. Some users also note losing the drive to drink alcohol, a secondary benefit relevant to those whose fibrosis has an alcohol-related component.

2. Tirzepatide: Strong Phase 2 Data, Phase 3 Underway

Tirzepatide is a dual agonist that activates two receptor types simultaneously: GLP-1 receptors and GIP receptors, where GIP stands for glucose-dependent insulinotropic polypeptide, a second incretin hormone that works alongside GLP-1 to regulate insulin release and fat storage. The combination produces more pronounced metabolic effects than GLP-1 activation alone, and the liver fibrosis data reflects this pattern. People know tirzepatide commercially as Mounjaro for type 2 diabetes and Zepbound for obesity. Neither carries current approval specifically for liver fibrosis, though Phase 3 trials are ongoing.

The evidence base for liver fibrosis is Phase 2, drawn from the SYNERGY-NASH trial, which enrolled 190 patients and published results in the New England Journal of Medicine in June 2024. At the highest tested dose, MASH resolution occurred in approximately 59 to 73 percent of participants depending on how the outcome was measured, compared to 17 percent on placebo. Fibrosis improvement in the range of 54 to 59 percent was also observed. These figures compare favorably to the semaglutide Phase 3 results, though the trials used different populations and designs, which makes direct comparison difficult.

Community use is active and growing. Users in Reddit forums focused on liver conditions and GLP-1 therapies have reported fibrosis stage improvements confirmed by imaging and labs, including transitions from advanced staging toward milder staging alongside dramatic reductions in liver fat and enzyme levels. Because tirzepatide is already FDA-approved for diabetes and obesity, physicians can and do prescribe it off-label for liver disease, and telemedicine access has made that practical for a larger group of patients.

The side effect profile closely resembles semaglutide: predominantly gastrointestinal, dose-dependent, and typically improving after the first weeks of a given dose. The same contraindications around medullary thyroid cancer and pancreatitis apply. As Phase 3 data matures, tirzepatide may become the second FDA-approved peptide option for liver fibrosis. For now it is used off-label under physician supervision by a substantial number of patients who cannot wait for the formal indication.

3. BPC-157: The Most-Studied Research Peptide for Liver Tissue

BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino-acid peptide originally derived from a protein found in human gastric juice. It has accumulated more than three decades of preclinical animal data across a range of organ systems, and within the liver fibrosis research community it is consistently described as the best-characterized preclinical peptide for this specific condition. No human clinical trial data has been published for BPC-157 in liver fibrosis as of 2026. Everything in the evidence record comes from animal models, in vitro studies, and the substantial body of user-reported experience from community protocols.

The preclinical data is specific and mechanistically grounded. In animal fibrosis models, BPC-157 has been shown to reduce COL1A1, the gene driving collagen production, by roughly 28 to 34 percent, and to reduce TGF-beta 1, the primary fibrosis-driving signaling molecule, by approximately 22 to 28 percent. The mechanism involves competition for the binding site between two proteins called FAK and paxillin, which together form part of the structural signaling apparatus that keeps hepatic stellate cells locked in their activated, scar-producing state. When that interaction is disrupted, the cells lose some of the scaffolding that sustains fibrogenesis. BPC-157 also increases MMP-13, an enzyme that actively breaks down existing collagen, while reducing TIMP-1, a protein that holds those collagen-degrading enzymes in check. Both effects point toward fibrosis regression rather than simply preventing new scar formation.

On the community side, BPC-157 is one of the most frequently mentioned research peptides in discussions about liver health. Users consistently group it with TB-500 as the two primary research peptide options for people exploring this space. Reports are anecdotal and unverified by biopsy, but they reflect a consistent pattern of interest and use across multiple platforms. One point of contention surfaced in community discussions: some users have raised the theoretical concern that BPC-157's healing and growth-promoting properties might behave differently in very advanced cirrhotic liver tissue compared to earlier-stage fibrosis. This is a contested and unresolved question, not a documented clinical finding, but it is worth noting as a reason for caution in end-stage disease.

Regulatory status matters here. The FDA placed BPC-157 in Category 2 bulk drug substance status in 2023, which means it cannot be legally compounded in the United States. It is sold as a research chemical through gray-market channels. The preclinical profile shows no hepatotoxicity in animal studies, and the compound is metabolized in the liver with a short half-life, but safety in humans with existing liver pathology is entirely unknown.

4. TB-500: Anti-Inflammatory Support for the Fibrotic Environment

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein found in high concentrations in blood platelets and wound-healing tissue throughout the body. Thymosin Beta-4 plays a well-established role in cell migration, tissue repair, and inflammation regulation. TB-500 refers specifically to the active region of the full protein that carries most of those biological properties. Like BPC-157, it is research-only with no published human clinical trials for liver fibrosis as of 2026. Its evidence base consists of animal models and in vitro work, plus a consistent presence alongside BPC-157 in community protocols focused on liver conditions.

The fibrosis-specific animal data shows TB-500 increasing fibrolysis, the process of breaking down existing scar tissue, by approximately 18 to 24 percent in studied models, while reducing alpha-smooth muscle actin by a similar margin. Alpha-smooth muscle actin is the protein that marks hepatic stellate cells in their activated state, so a reduction in its expression indicates the cells are shifting back toward quiescence rather than continuing to drive fibrogenesis. The proposed mechanism involves the NLRP3 inflammasome, an intracellular protein complex that senses cellular stress and drives the production of pro-inflammatory and pro-fibrotic signaling molecules. By regulating NLRP3 activity, TB-500 appears to reduce the inflammatory environment that keeps stellate cells active and scar production ongoing.

TB-500 also upregulates MMP-13, placing it in a similar mechanistic space as BPC-157 on the collagen-degradation side of the equation. This overlap is part of why the two compounds appear together so consistently in community discussions: they address overlapping but not identical parts of the fibrotic process, and some protocols combine them on that basis. Whether combination produces genuinely additive effects in the liver has not been studied in any controlled setting.

Availability follows the same pattern as BPC-157: sold as a research chemical through gray-market channels, not approved by the FDA or any Western regulatory body for any indication. Athletes should be aware that Thymosin Beta-4 and its fragments appear on the WADA Prohibited List. Human Phase 1 data exists for the full Thymosin Beta-4 protein in healthy adults, not for TB-500 specifically and not in people with liver disease. In that Phase 1 work, no toxicities were reported and liver function tests remained normal. That is the extent of the available human safety reference point.

5. Ovagen: A Liver-Derived Peptide Bioregulator from Eastern European Research

Ovagen is a peptide bioregulator, a category of short peptide complexes derived from specific organ tissues and developed primarily through Soviet and Russian military and gerontological research programs from the mid-twentieth century onward. The originating institution is the St. Petersburg Institute of Bioregulation and Gerontology. Ovagen is derived from fish liver tissue and contains short peptide sequences, typically two to four amino acids in length, that are theorized to act as organ-specific biological signals for hepatocytes, the primary working cells of the liver.

The proposed mechanism differs from the receptor-agonist or cytoskeletal approaches elsewhere on this list. Peptide bioregulators are thought to work by delivering short amino acid sequences that interact with liver-specific gene expression, acting as epigenetic signals that encourage hepatocytes to upregulate repair, renewal, and normal protein synthesis. The theory has biological plausibility, but the evidence supporting it in a Western peer-reviewed context is thin. Most published literature on this product class originates from the Russian research institutions that developed it, is frequently not indexed in major databases like PubMed, and has not been replicated by independent groups using controlled trial designs.

No large-scale human randomized controlled trials for Ovagen in liver fibrosis have been published in indexed journals. What exists is the originating research tradition and community interest among people exploring complementary approaches to liver health. Ovagen is sold as a dietary supplement in most markets, available without a prescription, and does not carry a drug classification. The short peptide sequences in the product are generally expected to be degraded in the gastrointestinal tract, which raises unresolved questions about bioavailability that the available literature does not adequately address.

The honest assessment: Ovagen belongs in a guide about what people actually use and discuss for liver fibrosis because it genuinely circulates in those conversations, particularly among people exploring the broader peptide bioregulator category. Its evidence is not comparable to BPC-157's preclinical depth or semaglutide's Phase 3 human trials. It sits at the experiential end of the evidence range, with theoretical mechanisms, a supplement-grade safety profile, and no clinical validation for the liver fibrosis indication.

6. Svetinorm: Another Hepatocyte-Targeting Bioregulator

Svetinorm is a second peptide bioregulator derived from liver tissue, closely related to Ovagen in both origin and proposed mechanism. Both come from the same Russian research tradition and the same institutional framework at the St. Petersburg Institute of Bioregulation and Gerontology. Both are composed of short hepatocyte-targeting peptide sequences. Both are marketed as dietary supplements rather than drugs. The practical distinction between the two products in terms of composition and proposed action is not clearly defined in the available Western literature, and they are frequently grouped together or used interchangeably in bioregulator product lines.

Svetinorm's claimed mechanism follows the same organ-specific bioregulation theory as Ovagen: short peptide sequences that signal hepatocytes to support liver cell renewal, protein synthesis, and repair processes. The proposed epigenetic dimension, the idea that these short sequences interact with DNA-level gene expression, is consistent with broader bioregulator theory but has not been demonstrated for Svetinorm specifically in indexed, independently replicated studies.

The evidence situation here is the same as for Ovagen, and it is stated plainly for the same reason. No large-scale human clinical trial data exists for Svetinorm in liver fibrosis in indexed Western databases. The research basis is Eastern European in origin, limited in scope, and has not been validated through the trial designs Western regulatory frameworks require. This is what the evidence actually is, and it is the reason this entry sits last on the list rather than higher. That positioning reflects where Svetinorm stands in terms of documented research presence, not a statement that it has no place in an informed discussion of what people use.

People interested in the peptide bioregulator class for liver support will encounter both Ovagen and Svetinorm together. Both carry a low-risk profile from a safety standpoint given their supplement classification and the general expectation that short peptide chains are degraded in digestion. Both lack the mechanistic specificity and trial replication that would allow a confident clinical recommendation. If you are drawn to this category, the honest frame is that you are working with a very limited evidence base and should approach it accordingly.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides legally available for liver fibrosis?

Semaglutide (Wegovy) is the only compound on this list with FDA approval specifically for liver fibrosis, granted in August 2025 for patients with MASH and F2 to F3 staging. Tirzepatide is FDA-approved for diabetes and obesity and can be prescribed off-label by physicians for liver conditions. BPC-157 and TB-500 are research chemicals that cannot be legally compounded in the United States under current FDA rules. Ovagen and Svetinorm are sold as dietary supplements and do not require a prescription in most markets, though neither holds any drug approval.

How do GLP-1 agonists differ from research peptides for this goal?

GLP-1 agonists like semaglutide and tirzepatide work primarily by improving the metabolic conditions that drive liver fibrosis, reducing fat accumulation, insulin resistance, and systemic inflammation. Research peptides like BPC-157 and TB-500 are studied for more direct effects on hepatic stellate cells and the enzymes that build and break down scar tissue. The practical difference is that GLP-1 agonists have human trial data supporting their use, require a prescription, and are administered under physician oversight, while BPC-157 and TB-500 remain in the preclinical stage with no human safety data in people who already have liver disease.

Is liver fibrosis reversible with these compounds?

Fibrosis at stages F1 through F3 is considered potentially reversible, and this is where most of the research showing measurable improvement has been conducted. Semaglutide's Phase 3 trial showed one-stage fibrosis reduction in 37 percent of patients. Tirzepatide's Phase 2 data showed fibrosis improvement in a similar range. Animal research with BPC-157 and TB-500 shows reductions in fibrosis markers in earlier-stage models. Cirrhosis at stage F4 is generally considered irreversible, and none of the compounds on this list have demonstrated reliable reversal of end-stage cirrhotic changes in human studies.

What safety concerns are specific to people with existing liver disease?

The liver metabolizes most drugs and peptides, so existing liver damage changes how compounds are processed and cleared. Semaglutide has been studied in patients with compensated cirrhosis and shows no documented hepatotoxicity. For BPC-157, TB-500, and the bioregulators, human safety data in people with liver disease simply does not exist. Preclinical studies with BPC-157 show no hepatotoxicity in healthy animal livers, but that does not establish safety in a fibrotic or cirrhotic liver. Anyone with liver disease should work with a physician before introducing any compound on this list, including supplement-grade options like Ovagen and Svetinorm.

How long does it take to see fibrosis improvement?

In the ESSENCE trial, measurable fibrosis improvement with semaglutide was assessed at 72 weeks of treatment, reflecting the reality that meaningful structural change in liver tissue accumulates slowly over months. Tirzepatide's SYNERGY-NASH trial ran for a similar duration. For BPC-157 and TB-500, no human timeline has been established because no human trials exist. Community reports vary widely and cannot be taken as representative given the absence of controlled conditions and individual variation in disease severity.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for liver fibrosis in one place.